Skip to main content

Advertisement

Fig. 2 | BMC Cancer

Fig. 2

From: Sorafenib suppresses the epithelial-mesenchymal transition of hepatocellular carcinoma cells after insufficient radiofrequency ablation

Fig. 2

Sorafenib inhibited the enhanced migration and invasion abilities of HCC cells after insufficient RFA. The effects of sorafenib on migration (a) and invasion (b) of HepG2 and HepG2-H cells were shown. Error bars represent the SEM of data obtained in three independent experiments. P value <0.05 was considered statistically significant; **p < 0.01, ***p < 0.001

Back to article page